Medicine & Life Sciences
B-Cell Lymphoma
100%
Chimeric Antigen Receptors
89%
axicabtagene ciloleucel
60%
Mantle-Cell Lymphoma
48%
Cell- and Tissue-Based Therapy
46%
T-Lymphocytes
45%
Hodgkin Disease
36%
CD19 Antigens
32%
Radiotherapy
31%
Lymphoma, Large B-Cell, Diffuse
30%
Drug Therapy
29%
Adoptive Immunotherapy
26%
Lymphoma
25%
Rituximab
25%
Neurotoxicity Syndromes
24%
Therapeutics
23%
Survival
22%
Progression-Free Survival
21%
Lenalidomide
20%
Cytokine Release Syndrome
20%
Brentuximab Vedotin
19%
Neoplasms
19%
Recurrence
17%
Radiation
17%
Doxorubicin
16%
PCI 32765
15%
Positron Emission Tomography Computed Tomography
15%
Multiple Myeloma
15%
Dexamethasone
15%
Cyclophosphamide
14%
Critical Illness
14%
Positron-Emission Tomography
13%
Second Primary Neoplasms
12%
Combined Modality Therapy
12%
venetoclax
12%
Non-Hodgkin's Lymphoma
12%
Plasma Cell Leukemia
12%
Hematologic Neoplasms
11%
Splenic Rupture
11%
Stem Cell Transplantation
11%
Immunoglobulin Light-chain Amyloidosis
10%
Immunotherapy
10%
Busulfan
10%
Lactic Acidosis
10%
Organs at Risk
9%
Marginal Zone B-Cell Lymphoma
9%
Cell-Free Nucleic Acids
9%
Follicular Lymphoma
9%
Bortezomib
9%
Melphalan
9%